Marissa Benchea and Jeremy and Rachel Olimb to lead the Foundation’s volunteer advocacy base into a new chapter of CF
Site Search
The Cystic Fibrosis Foundation awarded up to $4.7 million to EnBiotix Inc. to study the potential use of inhaled colistin as an additional option to treat Pseudomonas infections in people with cystic fibrosis who are not responding to current treatments.
The Cystic Fibrosis Foundation awarded up to $3.5 million to Arrevus Inc. to test a potential treatment for pulmonary exacerbations in people with cystic fibrosis in a late phase clinical trial.
This milestone was reached nearly two years ahead of the initiative’s five-year commitment. However, the Foundation aims to continue to support infection research at the same pace as it has in the past three years.
The cystic fibrosis care model is evolving to support people living longer with CF and their increasingly diverse health needs. Catalyzed by the approval of Trikafta® and the COVID-19 pandemic, this adaptive and personalized care model encompasses novel ways to connect clinicians and patients.
CEO pledge is part of the Foundation’s ongoing commitment to strengthen the organization and better serve all people with CF
The Foundation, in collaboration with external community advisors, finalizes recommendations in area of Community to help foster more inclusion and improve the experiences of Black people living with and impacted by cystic fibrosis.
A transformative leader for more than two decades, Marshall will transition to advisory role